drugset / Trial / NCT04414605

Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis

NCT04414605

NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to determine whether oral Chinese herbal medicine in combination secukinumab is effective and safe in the treatment of severe psoriasis.

Timeline

Start
2020-06-04
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gu Ben Hua Yu Fang Traditional medicine (herbal / TCM) Oral
Subject Secukinumab Monoclonal antibody 300 mg Subcutaneous

Indications